Economic evaluation · women with persistent, recurrent, or metastatic cervical cancer
1 finding from 1 review
Overall survival · women with early breast cancer
Taxane‐containing chemotherapy leads to lower overall survival compared with any chemotherapy without taxane (high certainty).
1 finding from 1 review
Disease‐free progression · women with early breast cancer
Taxane‐containing chemotherapy leads to lower disease‐free progression compared with any chemotherapy without taxane (high certainty).
1 finding from 1 review
Quality of life · women with early breast cancer
1 finding from 1 review
Febrile neutropenia · women with early breast cancer
Taxane‐containing chemotherapy showed no clear difference in febrile neutropenia compared with any chemotherapy without taxane (moderate certainty).
1 finding from 1 review
Neuropathy (including grade 3/4 sensory or motor neuropathy, or both) · women with early breast cancer
Taxane‐containing chemotherapy probably leads to higher neuropathy (including grade 3/4 sensory or motor neuropathy, or both) compared with any chemotherapy without taxane (moderate certainty).
1 finding from 1 review
Cardiotoxicity (including grade 3/4 and congestive cardiac failure) · women with early breast cancer
Taxane‐containing chemotherapy showed no clear difference in cardiotoxicity (including grade 3/4 and congestive cardiac failure) compared with any chemotherapy without taxane (moderate certainty).
1 finding from 1 review
All‐cause mortality · Kaposi sarcoma in children with HIV‐1 infection
It is very uncertain whether combination Chemotherapy + ART changes mortality compared with single Agent Chemotherapy + ART (very low certainty).
1 finding from 1 review
RR 0.38 [0.24, 0.58]
50 participants
Very low
Event‐free survival · children, adolescents, and young adults with primary metastatic Ewing sarcoma
High‐dose chemotherapy followed by autologous haematopoietic cell… showed no clear difference in event‐free survival (reported as number of participants with… compared with conventional chemotherapy plus whole lung irradiation (low certainty).
1 finding from 1 review
Overall survival · children, adolescents, and young adults with primary metastatic Ewing sarcoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality‐adjusted survival · children, adolescents, and young adults with primary metastatic Ewing sarcoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Toxicity · children, adolescents, and young adults with primary metastatic Ewing sarcoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Progression‐free survival · children, adolescents, and young adults with primary metastatic Ewing sarcoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival · patients with extensive SCLC without previous treatment
1 finding from 1 review
Adverse effects · patients with extensive SCLC without previous treatment
1 finding from 1 review
Progression‐free survival · patients with epithelial ovarian cancer
Maintenance chemotherapy showed no clear difference in 3‐year PFS compared with observation (moderate certainty).
3 findings from 1 review
RR 1.07 [0.91, 1.25]
4 studies · 541 participants
Moderate
RR 1.06 [0.97, 1.17]
3 studies · 761 participants
Moderate
RR 0.96 [0.65, 1.41]
2 studies · 219 participants
Moderate
Progression‐free survival · patients with epithelial ovarian cancer
Maintenance chemotherapy showed no clear difference in 3‐year PFS compared with maintenance radiotherapy (low certainty).
3 findings from 1 review
RR 1.07 [0.75, 1.54]
1 study · 141 participants
Low
RR 0.86 [0.55, 1.37]
1 study · 141 participants
Low
RR 0.89 [0.51, 1.55]
1 study · 141 participants
Low
3‐year OS · patients with epithelial ovarian cancer
Maintenance chemotherapy showed no clear difference in 3‐year OS compared with maintenance radiotherapy (low certainty).
1 finding from 1 review
5‐year OS · patients with epithelial ovarian cancer
Maintenance chemotherapy showed no clear difference in 5‐year OS compared with maintenance radiotherapy (low certainty).
1 finding from 1 review
10‐year OS · patients with epithelial ovarian cancer
Maintenance chemotherapy showed no clear difference in 10‐year OS compared with maintenance radiotherapy (low certainty).
1 finding from 1 review